Healthcare Services

Global Chikungunya Market Analysis for 2026–2030 with Strategic Forecast Insights for Businesses

March 31, 2026April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Chikungunya Market By The End Of 2030?

The chikungunya market size has demonstrated significant growth in recent years. It is projected to increase from $0.65 billion in 2025 to $0.71 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.4%. The factors contributing to this historical growth include a rising occurrence of mosquito-borne viral infections, the expansion of endemic areas influenced by climate variability, the limited availability of approved vaccines, a predominant reliance on symptomatic treatment approaches, and various public health monitoring initiatives.

The chikungunya market is anticipated to experience robust expansion in the coming years. Its valuation is projected to reach $1 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.1%. This projected growth throughout the forecast period stems from factors such as heightened investments in vaccine research, an elevated emphasis on preventive healthcare, the broadening of vector control initiatives, an escalating need for swift diagnostic tools, and increased global health financing directed towards emerging diseases. Key trends anticipated during the forecast timeframe encompass the accelerated development of chikungunya vaccines, a growing uptake of antiviral treatment protocols, a sharpened focus on early detection of the disease, the broadening of supportive care options, and improved surveillance measures for mosquito-borne illnesses.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21137&type=smp

What Drivers Are Shaping The Future Growth Of The Chikungunya Market?

The chikungunya market is anticipated to expand due to the increasing prevalence of mosquito-borne diseases. These illnesses, such as chikungunya, dengue, and zika virus, spread to humans from infected Aedes mosquitoes, posing significant global public health challenges. The growing worldwide incidence of these diseases stems from climate change, urbanization, deforestation, stagnant water accumulation, inadequate vector control measures, increased global travel, and insecticide resistance. Chikungunya treatment assists patients by alleviating symptoms like fever, joint pain, and inflammation, thus improving overall comfort and mobility, reducing complication risks, and aiding recovery through hydration, pain management, and supportive care. For instance, in December 2024, according to the UK Health Security Agency, a UK-based government agency, between January and June 2024, reported dengue cases among returning travelers in England, Wales, and Northern Ireland surged to 473, marking a 201% increase compared to the 157 cases recorded during the same period in 2023. Hence, the increasing global prevalence of mosquito-borne diseases is a major impetus for the chikungunya market.

Which Segment Classifications Shape The Chikungunya Market?

The chikungunya market covered in this report is segmented –

1) By Type: Antiviral Drugs, Herbal And Complementary Treatments, Supportive Care, Vaccines

2) By Product Form: Liquid Form, Powder, Solid Form

3) By Disease Stage: Acute, Chronic, Post-Infection

4) By Sales Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Supermarkets

5) By End User: Caregivers, Healthcare Professionals, Patients

Subsegments:

1) By Antiviral Drugs: Nucleoside Analogues, Protease Inhibitors

2) By Herbal And Complementary Treatments: Ayurvedic Remedies, Homeopathic Treatments, Traditional Chinese Medicine

3) By Supportive Care: Pain Relievers (NSAIDs, Acetaminophen), Fluid Therapy, Physiotherapy

4) By Vaccines: Live-Attenuated Vaccines, Inactivated Vaccines, mRNA-Based Vaccines

Which Market Trends Are Creating New Opportunities In The Chikungunya Market?

Leading firms within the chikungunya market are prioritizing the creation of novel vaccines to boost immunity, avert disease spread, and tackle the increasing worldwide health challenge posed by chikungunya virus infections. A live attenuated chikungunya vaccine functions by employing a weakened variant of the chikungunya virus to trigger an immune response without inducing illness, thereby offering sustained defense. As an illustration, in November 2023, Valneva SE, a biotechnology firm based in France, revealed IXCHIQ, which is a live attenuated chikungunya vaccine that secured approval from the Food and Drug Administration (FDA), a US government entity. This authorization was granted via an accelerated approval pathway, predicated on anti-CHIKV neutralizing antibody titers, with its ongoing validity relying on the confirmation of clinical advantages through subsequent studies. Valneva also obtained a Priority Review Voucher (PRV) from the FDA, which the organization plans to convert into funds to support its ongoing research and development initiatives. Ixchiq is administered as a single intramuscular injection and contains a living, attenuated form of the chikungunya virus, potentially inducing symptoms in those who receive it that resemble chikungunya illness.

Which Companies Are Expanding Their Footprint In The Chikungunya Market?

Major companies operating in the chikungunya market are F Hoffmann‑La Roche Ltd, Merck & Co Inc, Takeda Pharmaceutical Company Limited, Evotec SE, Valneva SE, Vaxart Inc, Inovio Pharmaceuticals Inc, Bharat Biotech International Limited, Moderna Inc, Emergent BioSolutions Inc, GlaxoSmithKline plc, Sanofi Pasteur, Instituto Butantan, Indian Immunologicals Limited, Zydus Lifesciences, BioNTech SE, Novavax Inc, Bavarian Nordic A S, Auro Vaccines LLC, Najit Technologies Inc, Clayton Biotechnologies Inc, Medigen Vaccine Biologics Corp

Read the full chikungunya market report here:

https://www.thebusinessresearchcompany.com/report/chikungunya-global-market-report

Which Geographic Regions Are Influencing Demand In The Chikungunya Market?

North America was the largest region in the chikungunya market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chikungunya market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Chikungunya Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21137&type=smp

Browse Through More Reports Similar to the Global Chikungunya Market 2026, By The Business Research Company

Chemotherapy Induced Anemia Global Market Report

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

Chemotherapy Induced Myelosuppression Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-myelosuppression-treatment-global-market-report

Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795